SCHEMBL3185693

SCHEMBL3185693

CC(C)(C)c1cc(NC(=O)Nc2ccc(Cl)cc2)n(-c2cccc(CC(N)=O)c2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 18/20 1.00
DDR2 Q16832 4/20 0.75
SRC P12931 1/20 0.75
MAPK9 P45984 1/20 0.75
RAF1 P04049 1/20 0.74
BRAF P15056 1/20 0.74
EPHB2 P29323 1/20 0.74
MAPK13 O15264 6/20 0.73
MAPK12 P53778 6/20 0.73
MAPK11 Q15759 6/20 0.73
MAPT P10636 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4303670 0.92 MAPK14 (0.86) MAPK14DDR2SRCMAPK9RAF1
SCHEMBL13857351 0.92 MAPK14 (0.85) MAPK14DDR2SRCMAPK9RAF1
SCHEMBL2085734 0.91 MAPK14 (0.86) MAPK14DDR2SRCMAPK9RAF1
SCHEMBL2082430 0.90 MAPK14 (0.82) MAPK14DDR2SRCMAPK9MAPK13
SCHEMBL2616997 0.90 MAPK14 (0.82) MAPK14DDR2SRCMAPK9MAPK13
SCHEMBL2083986 0.90 MAPK14 (1.00) MAPK14DDR2SRCMAPK9RAF1
SCHEMBL13923906 0.89 MAPK14 (0.80) MAPK14DDR2SRCMAPK9RAF1
SCHEMBL2083238 0.89 MAPK14 (0.80) MAPK14DDR2SRCMAPK9RAF1
SCHEMBL2081374 0.89 MAPK14 (0.84) MAPK14DDR2SRCMAPK9MAPK13
SCHEMBL2081795 0.88 MAPK14 (0.79) MAPK14DDR2SRCMAPK9RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737283-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2010-06-15 US disclosed
US-7737283-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2010-06-15 US disclosed
US-7737283-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2010-06-15 US disclosed
US-7666895-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2010-02-23 US disclosed
US-7666895-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2010-02-23 US disclosed
US-7666895-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2010-02-23 US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 US disclosed
EP-1836173-A4 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2009-07-08 EP disclosed
WO-2007008917-A2 MODULATION OF PROTEIN FUNCTIONALITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2007-01-18 WO disclosed
US-7144911-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS LLC (US) 2006-12-05 US disclosed
WO-2006081034-A2 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2006-08-03 WO disclosed
US-20050288286-A1 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC 2005-12-29 US disclosed
EP-1585734-A2 ANTI-INFLAMMATORY MEDICAMENTS Deciphera Pharmaceuticals, LLC (US) 2005-10-19 EP disclosed
EP-1585827-A2 MODULATION OF PROTEIN FUNCTIONALITIES Deciphera Pharmaceuticals, LLC (US) 2005-10-19 EP disclosed
US-20040180906-A1 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC 2004-09-16 US disclosed
US-20040171075-A1 Modulation of protein functionalities DECIPHERA PHARMACEUTICALS, LLC 2004-09-02 US disclosed
WO-2004060306-A2 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2004-07-22 WO disclosed
WO-2004061084-A2 MODULATION OF PROTEIN FUNCTIONALITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288286-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF MAPK14 56/4885DDR2 3555/4885SRC 295/4885
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS ABL2, ABL1, PTK2 MAPK14 80/4885DDR2 888/4885SRC 4/4885
US-20040180906-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF MAPK14 56/4885DDR2 3555/4885SRC 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.